Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013

Phase 1BAT8013Positive

AI Analysis

Summary

Bio-Thera Solutions has initiated dosing in a Phase I clinical trial of BAT8013, an antibody-drug conjugate targeting CD25, in patients with advanced solid tumours.

Clinical Trial Data

Phase

Phase I

Outcome Details

Dosing commenced in Phase I trial

Importance:5/10

Sentiment:

0.30

ADCCD25solid tumourstrial initiation

Related Companies

$CBDY $SLDB $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on July 24, 2026 8:42 AM

Read Original